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Abstract
The pathogenesis of human spontaneous abortion involves a complex interaction of several genetic
and environmental factors. The firm association between increased homocysteine concentration
and neural tube defects (NTD) has led to the hypothesis that high concentrations of homocysteine
might be embryotoxic and lead to decreased fetal viability. There are several genetic
polymorphisms that are associated with defects in folate- and vitamin B12-dependent homocysteine
metabolism. The methylenetetrahydrofolate reductase (MTHFR) 677C>T and 1298A>C
polymorphisms cause elevated homocysteine concentration and are associated with an increased
risk of NTD. Additionally, low concentration of vitamin B12 (cobalamin) or transcobalamin that
delivers vitamin B12 to the cells of the body leads to hyperhomocysteinemia and is associated with
NTD. This effect involves the transcobalamin (TC) 776C>G polymorphism. Importantly, the
biochemical consequences of these polymorphisms can be modified by folate and vitamin B12
supplementation. In this review, I focus on recent studies on the role of hyperhomocysteinemia-
associated polymorphisms in the pathogenesis of human spontaneous abortion and discuss the
possibility that periconceptional supplementation with folate and vitamin B12 might lower the
incidence of miscarriage in women planning a pregnancy.
Homocysteine metabolism and genetic 
polymorphisms – an overview
Accumulating evidence suggest that the sulfur-containing
amino acid homocysteine plays a role in various develop-
mental disorders [1]. Two main factors affect homo-
cysteine concentration in humans: diet (mainly intake of
folate and vitamin B12) and polymorphisms in genes that
encode enzymes or transport proteins involved in folate-
and vitamin B12-dependent homocysteine metabolism,
the so called one-carbon metabolism, which is a complex
series of metabolic pathways crucial for DNA synthesis
and repair and a wide range of methylation reactions (Fig.
1).
Methylenetetrahydrofolate reductase (MTHFR, EC
1.5.1.20) is a key enzyme in one-carbon metabolism. The
enzyme catalyzes the conversion of 5,10-methylenetet-
rahydrofolate into 5-methyltetrahydrofolate, the predom-
inating circulating form of folate. 5-
methyltetrahydrofolate participates in the vitamin B12-
dependent remethylation of homocysteine to methionine
that is converted to S-adenosylmethionine that serves as a
methyl group donor in the methylation of DNA, proteins,
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neurotransmitters and phospholipids [2]. MTHFR gene
polymorphisms are commonly associated with hyperho-
mocysteinemia [3,4]. In pregnant women this is a risk fac-
tor for neural tube defects (NTD) [5,6] and recurrent
embryo loss [7-9] as discussed thoroughly in three recent
reviews [10-12]. Recently, Gris et al. also reported an asso-
ciation between increased levels of homocysteine and a
first early pregnancy loss [13]. The best characterized
MTHFR genetic polymorphism consists of a 677C>T tran-
sition which results in an alanine to valine substitution in
the predicted catalytic domain of MTHFR [3]. This substi-
tution renders the enzyme thermolabile, and homozy-
gotes and heterozygotes have about a 70% and 35%
reduced MTHFR activity in vitro, respectively. Homozygos-
ity for the 677T allele is associated with elevated homo-
cysteine levels, predominantly in individuals who have a
low plasma folate level [14]. Furthermore, the level of
plasma homocysteine can be lowered in homozygous
individuals by folate supplementation [15]. About half
the general population carries at least one mutated allele
and the frequency of the homozygous mutated genotype
(677TT) ranges from 1 to 20% depending on the popula-
tion [16]. A second common polymorphism in the
MTHFR gene is a 1298A>C transition which results in a
glutamate to alanine substitution within a presumed reg-
ulatory domain of MTHFR [4,17]. The 1298C allele has
been reported to lead to decreased enzyme activity,
although not to the same extent as the 677T allele
[4,17,18]. Individuals who are compound heterozygous
for the 677T and 1298C alleles, which produces a 677CT/
1298AC genotype, have according to some studies 40–
50% reduced MTHFR activity in vitro and a biochemical
Overview of the human folate- and vitamin B12-dependent homocysteine metabolism indicating its one-carbon donors and  acceptors involved in methyl group biogenesis and DNA synthesis. Figure 1
Overview of the human folate- and vitamin B12-dependent homocysteine metabolism indicating its one-carbon donors and 
acceptors involved in methyl group biogenesis and DNA synthesis. MTHFR, methylenetetrahydrofolate reductase; MSR, 
methionine synthase reductase; dUMP, deoxyuridylate; dTMP, deoxythymidylate.
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profile similar to that seen among 677T homozygotes
with increased homocysteine levels and decreased folate
levels [4,17]. However, recent results indicate that the
MTHFR 1298A>C polymorphism does not contribute sig-
nificantly to hyperhomocysteinemia, neither by itself nor
in combination with the 677C>T polymorphism [19,20],
and the phenotypic effect of the polymorphism has also
been questioned from a biochemical point of view [21]. It
must, however, be borne in mind that the absence of a
biochemical phenotype in vitro does not necessarily rule
out the possible importance of the 1298A>C polymor-
phism in vivo, for instance during times of high folate
requirement, such as pregnancy [22].
Yet another common genetic polymorphism that influ-
ences homocysteine concentration is a C>G transition at
position 776 (776C>G) in the transcobalamin (TC) gene
[23]. The transition results in a substitution of arginine for
proline at codon 259 and is the major determinant of the
TC phenotypic variability in Caucasian populations
[24,25]. TC is the critical transporter that delivers vitamin
B12 to peripheral tissues and heterozygosity for the poly-
morphism has been associated with hyperhomocysteine-
mia [25]. The wild-type 776C allele has positive effects on
TC plasma levels [25-27], which may be important for
efficient vitamin B12 delivery to the cells of the growing
embryo.
Folate, vitamin B12 and homocysteine in 
embryonic development
One-carbon metabolism during embryonic development
has been studied mostly with regard to the development
of the nervous system. Pregnant women who are folate
deficient have a greatly increased risk of NTD in their
babies and periconceptional folate supplementation pro-
tects against this effect [12,28-31]. The molecular events
that lead to NTD due to folate deficiency are not known
but may include insufficient methylation of crucial
metabolites in the developing embryo and/or abnormali-
ties in neural cell proliferation, differentiation and apop-
tosis, which may be due to DNA nucleotide
misincorporation that accompanies folate deficiency in
proliferating cells [2]. It seems likely that these fundamen-
tal events also might lead to decreased fetal viability. In
agreement with this view, a recent population-based case-
control study showed an increased risk of early spontane-
ous abortion among pregnant women with low plasma
folate levels [32]. Vitamin B12 deficiency during pregnancy
results in elevated homocysteine concentration in the
embryo and increases the incidence of NTD
[26,31,33,34]. In addition, hereditary deficiency of
transcobalamin results in profound neurological abnor-
malities and mental retardation [35]. Three studies envis-
age a direct embryotoxic effect of homocysteine [36-38].
In one study exposure of chick embryos to homocysteine
resulted in defects both of the heart and the neural tube
[36], while exposure of mouse and rat embryos to homo-
cysteine in two other studies mainly resulted in growth
retardation and abnormalities of somite development,
but not in neurulation defects or other teratogenic effects
[37,38]. The precise mechanism of homocysteine toxicity
remains elusive but there are several hypotheses, some of
which have been tested experimentally. The toxic effect of
homocysteine in developing rat embryos may result from
increased formation of S-adenosylhomocysteine that
could inhibit critical methylation reactions [38]. Elevated
homocysteine concentration could also inhibit de novo
synthesis of deoxythymidylate (dTMP). Exposure of pro-
liferating B-lymphoid Raji cells to excess homocysteine or
methionine increases the uptake of exogenous thymidine
owing to inhibition of the thymidylate synthase-catalyzed
reaction in which deoxyuridylate (dUMP) is converted to
dTMP (Fig. 1) [39]. It is thought that 5,10-methylenetet-
rahydrofolate, a cofactor in this reaction, is depleted in the
presence of excess homocysteine due to increased demand
for 5-methyltetrahydrofolate to remove homocysteine by
methylation. This might induce DNA damage through
increased misincorporation of dUMP in place of dTMP in
DNA followed by excision-repair reactions, DNA strand
breaks, cell-cycle arrest and, ultimately, apoptosis. In con-
clusion, folate, vitamin B12 and homocysteine play several
fundamental roles in growing cells and thus in the devel-
oping embryo. It is also possible that homocysteine by
itself induces some of the developmental disorders previ-
ously attributed to folate and/or vitamin B12 deficiency.
MTHFR and TC genetic polymorphisms in 
human spontaneous abortion
Through their defects in folate- and vitamin B12-depend-
ent homocysteine metabolism, MTHFR and TC polymor-
phisms have been implicated as risk factors for several
developmental disorders, such as NTD [40-44], orofacial
clefting [45] and Down syndrome [46], although there are
studies failing to replicate these findings [47-51]. Interest-
ingly, Wenstrom et al. found a strong association between
fetal MTHFR 677T alleles, elevated homocysteine concen-
tration in amniotic fluid and neurotubular defects span-
ning the cervical-lumbar spine, lumbosacral spine, and
occipital encephalocele, but not anencephaly, exenceph-
aly or spina bifida confined to the sacrum [52]. The
authors conclude that the MTHFR 677T allele predisposes
only to certain types of NTD [52].
As mentioned earlier, maternal hyperhomocysteinemia is
a risk factor for recurrent embryo loss [7-9] and also for a
first early embryo loss [13]. In addition to these findings,
some studies have reported an association between mater-
nal MTHFR 677T alleles and increased risk of recurrent
spontaneous abortion [53-56] (Table 1). However, this
effect has not been replicated in other studies [57-63].Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/7
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Likewise, six studies found no association between mater-
nal 677T alleles and non-recurrent fetal loss [61,64-68],
but five of these only examined late fetal loss (fetal death
after 19 weeks or more of gestation). Aside from strong
bias toward late-pregnancy outcomes and nutritional and
ethnic differences between the study populations, one
explanation for the discrepant results may be that the
numbers of study participants have been relatively small,
yielding a low power, i.e. a low probability for detecting a
difference if there is one. It is also possible that fetal gen-
otypes would have produced clearer results. The common
effects of MTHFR and TC mutated alleles are lower bioa-
vailability of folate and vitamin B12 and increased homo-
cysteine concentration. Since vital cellular processes such
as proliferation and differentiation are dependent on
folate- and vitamin B12-mediated one-carbon metabo-
lism, these effects may be especially pronounced early in
embryogenesis when the cells undergo rapid proliferation
and differentiation [12]. Hence, it would be of special
interest to analyze spontaneously aborted embryos, not
just the mothers, for the MTHFR and TC polymorphisms.
Recently, four studies addressing this issue were under-
taken [22,69-71] (Table 1). Isotalo et al. reported high
prevalence of mutated MTHFR alleles in aborted embryos
[69]. However, their study group consisted of fetal tissue
samples from both spontaneous and therapeutic termina-
tions of pregnancy, which diminishes the interpretability
of the investigation. We undertook a similar study, except
that only spontaneously aborted embryos (fetal death
between sixth and twentieth week after conception) were
included. There was a significant odds ratio for spontane-
ous abortion of 14.2 (95% CI 1.78–113; p = 0.001) when
comparing the prevalence of one or more 677T and
1298C alleles versus the wild type combined genotype
(677CC/1298AA) in cases and controls, indicating that
the MTHFR polymorphisms may have a major impact on
fetal survival [22]. The prevalence of the mutated TC 776G
allele was significantly increased in aborted embryos
while the frequency of wild-type TC 776C homozygotes
was much lower among spontaneously aborted embryos
than controls (9.1% and 32.2%, respectively; p < 0.001)
[70]. These data are consistent with the view that the 776C
allele may have beneficial influences during embryogene-
sis, conceivably through its positive effect on vitamin B12
intracellular bioavailability, which among other things
results in reduced homocysteine concentration. Finally,
Table 1: Maternal and fetal MTHFR 677T alleles in human spontaneous abortion.
REFERENCE NUMBER OF PARTICIPANTS CASES/CONTROLS RESULT
Recurrent spontaneous abortion
Maternal genotypes
Foka et al.  [58] 80/100 No risk
Holmes et al.  [59] 173/67 No risk
Kumar et al.  [56] 24/24 Increased risk
Kutteh et al.  [60] 50/50 No risk
Lissak et al.  [55] 41/18 Increased risk
Murphy et al.  [61] 40/540 No risk
Nelen et al.  [53] 185/113 Increased risk
Pihusch et al.  [62] 102/128 No risk
Wramsby et al.  [63] 84/69 No risk
Non-recurrent spontaneous abortion
Maternal genotypesa
Alfirevic et al.  [64] 18/44 No risk
Gris et al.  [65] 232/464 No risk
Kupferminc et al.  [66] 12/110 No risk
Many et al.  [67] 40/80 No risk
Martinelli et al.  [68] 67/232 No risk
Murphy et al.  [61] 24/540 No risk
Spontaneous abortion
Fetal genotypes
Isotalo et al.  [69] 161/119 Increased risk b
Zetterberg et al.  [22] 80/125 Increased risk b
Zetterberg et al.  [71] 76/114 Increased risk c
a Five of these six studies examined late fetal loss (fetal death after 19 weeks or more of gestation) b Interaction between fetal MTHFR 677T and 
1298C alleles c Interaction between fetal MTHFR 677T and TC 776G allelesReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/7
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we addressed the possibility of a gene-gene interaction
between the MTHFR and TC polymorphisms in human
spontaneous abortion [71]. Embryos that had combined
MTHFR 677TT and TC 776CG or 776GG genotypes; gen-
otypes that individually are associated with impaired
homocysteine metabolism in adults, were at increased
risk for spontaneous abortion compared to embryos that
had only one of these genotypes. This indicates a detri-
mental interaction between the hyperhomocysteinemia-
associated MTHFR 677TT and TC 776CG or 776GG geno-
types during embryogenesis and further underscores the
linkage between decreased fetal viability and elevated
homocysteine concentration. Other candidate gene-gene
interactions that remain to be explored in spontaneous
abortion are between the MTHFR and TC genes and the
genes for cystathionine β-synthase [72], methionine syn-
thase [42] and methionine synthase reductase [73], which
all are involved in one-carbon metabolism and have been
examined in relation to NTD.
Another possible, but as yet unexplored, type of genetic
interaction in human spontaneous abortion is a maternal-
fetal interaction. The 677C>T polymorphism confers an
even higher risk for NTD if both the mother and her child
are homozygous for the 677T allele, as compared to if
only the mother or the child is homozygous [42]. Con-
ceivably, the homocysteine concentration in the embryo
would be even higher if both the mother and the embryo
carried hyperhomocysteinemia-associated MTHFR and
TC genotypes and, if the hypothesis of the embryotoxicity
of homocysteine were true, this would lead to even further
increased risk of spontaneous abortion.
Prevention of human spontaneous abortion by 
periconceptional B-vitamin supplementation
The MTHFR and TC polymorphisms are modifiable
genetic risk factors. Increased intake of folate [15] and
vitamin B12 (Zetterberg et al., unpublished data) neutral-
izes the negative effects of the mutated alleles on homo-
cysteine metabolism. The effect of folate supplementation
on prevention of NTD has been questioned [74], but gen-
erally it appears that daily consumption of 400 µg of
folate before conception and during early pregnancy
reduces the occurrence of NTD [29,30]. Moreover, the
impact of mandatory fortification of grain with folate on
the prevention of NTD was recently documented in the
United States where a 19% reduction in NTD birth preva-
lence was seen following folate food fortification,
although factors other than fortification may have con-
tributed to this decline [75]. It has been suggested that the
probable reduction in risk of pregnancy complications
may be more effective if a combination of folate and vita-
min B12 is given [31,76]. Hence, pregnant women that
carry hyperhomocysteinemia-associated MTHFR and TC
genotypes might benefit from supplementation with both
folate and vitamin B12 to reduce the risk of miscarriage.
Since the MTHFR and TC polymorphisms are very com-
mon, and since the data indicate that the fetal genotype is
as important as the maternal genotype, a general recom-
mendation of periconceptional supplementation with
folate and vitamin B12 may be considered. It should, how-
ever, be remembered that certain populations already
have adequate intake of folate and vitamin B12 even for
carriers of variant alleles. For instance traditional Mediter-
ranean diet is abundant in folate [77,78].
Can periconceptional B-vitamin supplementation lead to
any adverse effects? There is evidence for an increase in
twinning frequency with increased risk of pregnancy com-
plications following folate supplementation [79,80].
Moreover, a case-control study investigated the 677C>T
polymorphism in mothers with dichorionic twin preg-
nancies and found a lower frequency of the 677T allele
amongst mothers of twins compared with women who
gave birth to singletons [81]. The authors suggest that the
MTHFR 677T allele is protective against multiple pregnan-
cies and that folate supplementation might increase the
risk of twinning. However, recent results from a large pop-
ulation-based cohort study in China showed no evidence
for effects of folate supplementation on twinning fre-
quency [82]. Likewise, there was no evidence for associa-
tion between MTHFR genotype and twinning in mothers
of twins or for the loss of specific MTHFR genotypes dur-
ing twin pregnancies in a very recent large study of fami-
lies with twins and of twin pairs [83]. Lastly, there has
been some concern that folate supplements might
increase abortion rates by delaying very early abortions
that would not have been recognized as a pregnancy in the
absence of vitamin supplementation [84,85], but a large
population-based case-control study revealed no
association between high folate levels and increased risk
of spontaneous abortion [32]. In fact, a non-significant
trend toward a protective effect associated with high folate
levels was seen.
Taken together, the data reviewed in this article warrant
additional investigations exploring the potential benefi-
cial effects of periconceptional supplementation with
both folate and vitamin B12 in the prevention of spontane-
ous abortion.
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